Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label adalimumab maintenance in Crohn's disease (Hungary)
2004-002163-24Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Oct 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by Abbott Laboratories. Primary endpoints: Maintenance of clinical response and remission (CDAI) and Quality of life (IBDQ). Started Oct 2004; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2004-002163-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002163-24.